XTAI
1737
Market cap188mUSD
Oct 08, Last price
30.00TWD
1D
0.17%
1Q
-5.96%
Jan 2017
2.39%
IPO
9.21%
Name
Taiyen Biotech Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1952 and headquartered in Tainan, Taiwan, Taiyen Biotech Co., Ltd. is a multifaceted enterprise engaged in the global production and distribution of salt-based goods. The company offers a wide-ranging portfolio that includes various salt and seawater-derived chemical products, alongside an array of personal care items such as bath salts, specialty soaps, and shampoos. Beyond hygiene products, their offerings extend to beverages, drinking water, and oral and optical care solutions like toothpaste, mouthwash, and contact lens maintenance fluids. Taiyen also provides specialized salts for cleaning produce, as well as food items and additives. Furthermore, the company manufactures pharmaceutical products, encompassing both cosmetic formulations and environmental health medications. Its operations also include the import and export of general consumer goods and beauty products, complemented by expert consulting services in industrial salt technology, covering supply, implementation, and management.
Key people
Chieh-Han Li
General Manager · since 2025
Wei Su
Head of Finance & Accounting · since 2019
Director · since 2022
Director · since 2019
Wei-Yi Chu
Labor Director · since 2023
Hsien-Kuei Liao
Director · since 2017
Ya-Chuan Liu
Director · since 2025
Yen-Che Ting
Chairman of the Board · since 2024
Shih-Hao Wu
Independent Director · since 2022
Wen-Cheng Wu
Non-Executive Independent Director · since 2025
Xing-Yuan Wu
Non-Executive Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||